GenSight Biologics (OTCMKTS:GSGTF – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

This is a summary of recent ratings for GenSight Biologics and Pyxis Oncology, as provided by MarketBeat.com.

Pyxis Oncology has a consensus target price of $7.50, suggesting a potential upside of 92.80%. Given Pyxis Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than GenSight Biologics.

39.1% of Pyxis Oncology shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

This table compares GenSight Biologics and Pyxis Oncology’s net margins, return on equity and return on assets.

This table compares GenSight Biologics and Pyxis Oncology”s top-line revenue, earnings per share and valuation.

GenSight Biologics has higher earnings, but lower revenue than Pyxis Oncology.

Pyxis Oncology beats GenSight Biologics on 6 of the 8 factors compared between the two stocks.

(Get Free Report)

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

(Get Free Report)

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for GenSight Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenSight Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Cherry Hill Mortgage Investment Corporation (NYSE:CHMI) Receives Average Recommendation of “Hold” from Brokerages

Head-To-Head Contrast: Aercap (NYSE:AER) vs. Fifth Era Acquisition Corp I (NASDAQ:FERA)